Trial Profile
An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2016
Price :
$35
*
At a glance
- Drugs Gevokizumab (Primary)
- Indications Pyoderma gangrenosum
- Focus Proof of concept; Therapeutic Use
- Sponsors XOMA
- 13 Nov 2013 New trial record